Development of Follicle-Stimulating Hormone Receptor Binding Probes to Image Ovarian XenograftsChung-Wein Lee1, Lili Guo2, Daniela Matei2 and Keith Stantz1,2*
- Corresponding Author:
- Keith Stantz
Medical Physics Program, School of Health Science
Purdue University, Civil Engineering Building
550 Stadium Mall Drive, West Lafayette, IN 47907-2057, USA
E-mail: [email protected]
Received date: May 05, 2015; Accepted date: September 02, 2015; Published date: September 10, 2015
Citation: Lee CW, Guo L, Matei D, Stantz K (2015) Development of Follicle-Stimulating Hormone Receptor Binding Probes to Image Ovarian Xenografts. J Biotechnol Biomater 5:198. doi:10.4172/2155-952X.1000198
Copyright: © 2015 Lee CW, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The Follicle-Stimulating Hormone Receptor (FSHR) is used as an imaging biomarker for the detection of ovarian cancer (OC). FSHR is highly expressed on ovarian tumors and involved with cancer development and metastatic signaling pathways. A decapeptide specific to the FSHR extracellular domain is synthesized and conjugated to fluorescent dyes to image OC cells in vitro and tumors xenograft model in vivo. The in vitro binding curve and the average number of FSHR per cell are obtained for OVCAR-3 cells by a high resolution flow cytometer. For the decapeptide, the measured EC50 was 160 μM and the average number of receptors per cell was 1.7 x 107. The decapeptide molecular imaging probe reached a maximum tumor to muscle ratio five hours after intravenous injection and a dose-dependent plateau after 24-48 hours. These results indicate the potential application of a small molecular weight imaging probe specific to ovarian cancer through binding to FSHR. Based on these results, multimeric constructs are being developed to optimize binding to ovarian cells and tumors.